Building a pipeline of anti-inflammatory drugs

Our lead drug, otenaproxesul, is in clinical development for post-operative pain. Our second pipeline drug, ATB-352, addresses unmet needs in a specialized pain indication. Antibe’s Emerging Discovery Program is developing a new molecule targeting inflammatory bowel disease (“IBD”) as well as fortifying the IP position of our drugs and platform.

Development Pipeline

Click on a therapeutic candidate to learn more.

INVESTOR INFORMATION

Keep up-to-date—visit the Investor Dashboard for share information, our Corporate Presentation, financial statements, regulatory filings, the latest news and more—everything you need in one place.

OUR SCIENCE

Learn about the science behind our drug platform. See how Antibe’s lead drug aims to surpass current solutions. Investigate a diagram detailing hydrogen sulfide’s multiple roles in the human body.

Attention

This is an external link. Click “OK” to continue.

CANCEL OK